Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal.

Skelton KH, Oren D, Gutman DA, Easterling K, Holtzman SG, Nemeroff CB, Owens MJ.

Eur J Pharmacol. 2007 Sep 24;571(1):17-24. Epub 2007 Jun 5.

PMID:
17610870
2.

The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal.

Skelton KH, Gutman DA, Thrivikraman KV, Nemeroff CB, Owens MJ.

Psychopharmacology (Berl). 2007 Jun;192(3):385-96. Epub 2007 Feb 13.

PMID:
17297634
3.
4.

The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems.

Gilmor ML, Skelton KH, Nemeroff CB, Owens MJ.

J Pharmacol Exp Ther. 2003 May;305(2):434-9. Epub 2003 Jan 24.

PMID:
12606697
5.

The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.

Gutman DA, Owens MJ, Skelton KH, Thrivikraman KV, Nemeroff CB.

J Pharmacol Exp Ther. 2003 Feb;304(2):874-80.

PMID:
12538845
6.

Are CRF receptor antagonists potential antidepressants?

O'Brien D, Skelton KH, Owens MJ, Nemeroff CB.

Hum Psychopharmacol. 2001 Jan;16(1):81-87.

PMID:
12404602
7.

The neurobiology of urocortin.

Skelton KH, Owens MJ, Nemeroff CB.

Regul Pept. 2000 Sep 25;93(1-3):85-92. Review.

PMID:
11033056
9.

Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.

Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ.

J Pharmacol Exp Ther. 2000 Aug;294(2):588-97.

PMID:
10900236

Supplemental Content

Loading ...
Support Center